Study With Two Coenzyme Q10 Products

Comparative Single-dose Bioavailability Clinical Study of Two Different Coenzyme Q10 Products

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06736366

Acronym

Co10_2024

Enrollment

Registered

2024-12-16

Start date

2024-12-05

Completion date

2025-06-30

Last updated

2025-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coenzyme Q Deficiency

Keywords

single dose bioavailability, Coenzyme Q10

Brief summary

The randomized, open-label, two period crossover single-dose bioavailability study with two coenzyme Q10 products

Detailed description

The randomized, open-label, two period crossover single-dose bioavailability study with two coenzyme Q10 products will include 35 subjects who will test two different coenzyme Q10 products. Plasma concentration of coenzyme Q10 will be measured.

Interventions

DIETARY_SUPPLEMENTDietary supplement - Active comparator

Single dose intervention with Standard product Coenzyme Q10 (ubiquinone); 2 capsules - 100 mg total coenzyme Q10

DIETARY_SUPPLEMENTDietary supplement - Experimental product

Single dose intervention with Experimental product; BMT® coenzyme Q10; 2 capsules - 100 mg total coenzyme Q10

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

SCREENING

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

50 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* subject informed consent form * aged between 50 and 65 years old * body mass for women 70± 5 kg and for men 85± 5 kg * non-smoking * healthy, without cardio-vascular diseases, diabetes, neurodegenerative diseases * absence of any prescribed medication during the study * willing to avoid a consumption of any food supplements at least 2 weeks before and during the study

Exclusion criteria

* cardio-vascular diseases, diabetes, neurodegenerative diseases, gastrointestinal disorders, pregnancy, breast-feeding * intake of any food supplements within two week of the beginning of the study * drug or alcohol abuse

Design outcomes

Primary

Measure	Time frame	Description
Plasma levels of Coenzyme Q10	At Baseline	Plasma levels of Coenzyme Q10 will be measured by high-performance liquid chromatography (HPLC) with electrochemical detection and a post-analytical reducing column, using a Nanospace HPLC apparatus.

Countries

Slovenia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 30, 2026